In this issue:
Long-term outcomes of patients with active melanoma brain metastases treated with nivolumab + ipilimumab
Crossover and rechallenge with pembrolizumab in recurrent patients after complete resection of high-risk stage III melanoma
Association between sex and ICI outcomes for patients with melanoma
Effect of immunotherapy time-of-day infusion on OS in advanced melanoma
Immune-modulatory vaccine against IDO/PD-L1 + nivolumab in metastatic melanoma
Ipilimumab +/- nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade
Long-term outcomes with nivolumab + ipilimumab or nivolumab alone vs ipilimumab in patients with advanced melanoma
Improved prognosis and enhanced immunogenicity in high-risk MUP
Relatlimab + nivolumab versus nivolumab in untreated advanced melanoma
TERT promoter mutations are associated with longer PFS and OS in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitors
Please login below to download this issue (PDF)